Menu Close


Ninnion is committed to increasing the industry’s collective understanding of psychedelic therapeutics. Keep up with our news and resources to get the latest on company updates, announcements, key research and findings.

Press Releases

Ninnion Therapeutics to Webcast Live at April 27th

April 25th, 2022 — Ninnion, based in Austin, focused on creating next generation psychedelic therapies designed for payer reimbursement, today announced that Jeremy M Caudill, Founder and CEO will present live at on April 27th, 2022

DATE: April 27th, 2022
TIME: 12-12:30pm ET

APRIL 7th, 2022 – Ninnion, a clinical-stage pharmaceutical company focused on developing next-generation psychedelic therapeutics, today announced the commencement of a first-of-its-kind pre-clinical development of NIN-S119. NIN-S119 is a proprietary, short-acting substituted tryptamine to treat patients recovering from ischemic stroke.

MARCH 23rd, 2022 – Ninnion, a clinical-stage pharmaceutical company focused on developing next-generation psychedelic therapeutics today announced the formation of its Scientific Advisory Board (SAB). The board is composed of key opinion leaders in pharmaceutical development and psychedelics research, including Rick Strassman, MD, Charles B Nemeroff, MD, and chaired by Bill W. Massey,  Ninnion’s Chief Development Officer.

NOVEMBER 8th, 2021 – Ninnion, LLC, a pharmaceutical startup company focused on psychedelic therapeutics for the payer reimbursable market, is pleased to announce the addition of Dr. Bill W. Massey as its Chief Development Officer. 


We often have updates about our work at Ninnion. Some of the highlights within the last year include:

January 17, 2021
Our team signed the MoU agreement to create a psychedelic drug discovery and development joint venture. 

February 15, 2021
Dr. Bill Massey joined our scientific advisory board. 

March 2021
Dr. Atilla Szabo and Dr. Ede Frecska joined our scientific advisory board. 

Ninnion joins with one of our partners to announce a software development agreement focused on ketamine.  

To learn more about our work, please contact Ninnion today.

November 20, 2020
World-renowned psychedelic researcher Dr. Rick Strassman, MD, joined our scientific advisory board.

December 15, 2020
The head of the VA ketamine program at UCSF, Dr. Tobias Marton, joined our scientific advisory board.

January 15, 2021
Dr. Patrick Finan, a psychiatric researcher at Johns Hopkins, joined our scientific advisory board.